Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-08-02
2011-08-02
Chernyshev, Olga N (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S192100, C424S193100, C424S194100, C514S001100, C514S021200, C514S017800
Reexamination Certificate
active
07988969
ABSTRACT:
Compositions that include an Aβ polypeptide linked to a non-Aβ polypeptide are described, as well as methods of using such compositions.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5231000 (1993-07-01), Majocha et al.
patent: 5260308 (1993-11-01), Poduslo et al.
patent: 5262332 (1993-11-01), Selkoe
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5854204 (1998-12-01), Findeis et al.
patent: 2003/0082191 (2003-05-01), Podulso
patent: 2004/0022736 (2004-02-01), Poduslo et al.
patent: 2004/0142872 (2004-07-01), Poduslo
patent: WO 95/11311 (1995-04-01), None
patent: WO-96/40248 (1996-12-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 01/74374 (2001-10-01), None
patent: WO-02/42462 (2002-05-01), None
patent: WO 02/42462 (2002-05-01), None
Huse, WD et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda,” Science, Dec. 8, 1989, 246: 1275-1281.
Vallette, F et al., “Construction of mutant and chimeric genes using the polymerase chain reaction,” Nucl. Acids Res., 1989, 17: 723-733.
de St Groth SF and Scheidegger D, “Production of monoclonal antibodies: strategy and tactics,” J Immunol. Methods, 1980, 35(1-2):1-21.
European Search Report (Supplementary), EP 02761522, European Patent Office, Nov. 14, 2007.
Bickel et al., Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease, Bioconj. Chem., 5:119-125, 1994.
European Search Report (Supplementary, Partial), EP 02761522.8, European Patent Office, Jun. 29, 2007.
Poduslo et al., Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier, Neuroreport, 12(15):3197-3200, 2001.
Wu et al., Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to human insulin receptor, J. Clin. Invest., 100(7):1804-1812, 1997.
Zlokovic et al., Glycoprotein 330-megalin: probable role in receptor-mediated transport of apolipoproteinJalone and in a complex with Alzheimer disease amyloid beta at the blood-cerebrospinal fluid barriers, Proceedings of the National Academy of Sciences of USA, 93(9):4229-4234, 1996.
Caravan et al., “Gadolinium (III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications,”Chem. Rev., 1999, 99:2293-2352.
Chen et al., “A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease,”Nature, 2000, 408:975-979.
Curtet et al., “Polylysine-Gd-DTPA, and Polylysine-Gd-DOTA,, Coupled to Anti-CEA F(ab′)2Fragments as Potential Immunocontrast Agents,”Invest. Radiol., 1998, 33(10):752-761.
De St. Groth and Scheidegger, “Production of Monoclonal Antibodies: Strategies and Tactics,”J. Immunol. Methods, 1980, 35:1-21.
DeMattos et al., “Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease,”Proc. Natl. Acad. Sci. USA, 2001, 98(15):8850-8855.
Fraser et al., “Fibril Formation by Primate, Rodent, and Dutch-Hemorrhagic Analogues of Alzheimer Amyloid β-Protein,”Biochemistry, 1992, 31:10716-10723.
Hilbich et al., “Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4,”Eur. J. Biochem., 1991, 201:61-69.
Janus et al., “Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease,”Nature, 2000, 408:979-982.
Kalra, “Circumventing leptin resistance for weight control,”Proc. Natl. Acad. Sci. USA, 2001, 98(8):4279-4281.
Lauffer et al., “Preparation and Water Relaxation Properties of Proteins Labeled with Paramagnetic Metal Chelates,”Magn. Reson. Imaging, 1985, 3:11-16.
Le et al., “Amyloid β42Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1,”J. Neuroscience, 2001, 21:1-5.
Morgan et al., “Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease,”Nature, 2000, 408:982-985.
Müller-Gartner, “Imaging techniques in the analysis of brain function and behaviour,”TIB Tech., 1998, 16:122-130.
Poduslo and Curran, “Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy,”Proc. Natl. Acad. Sci. USA, 1992, 89:2218-2222.
Poduslo et al., “Macromolecular permeability across the blood-nerve and blood-brain barriers,”Proc. Natl. Acad. Sci. USA, 1994, 91:5705-5709.
Poduslo and Curran, “Polyamine Modification Increases the Permeability of Proteins at the Blood-Nerve and Blood-Brain Barriers,”J. Neurochemistry, 1996, 66:1599-1609.
Poduslo et al., “Permeability of Proteins at the Blood-Brain Barrier in the Normal Adult Mouse and Double Transgenic Mouse Model of Alzheimer's Disease,”Neurobiol. Disease, 2001, 8:555-567.
Saito et al., “Vector-mediated delivery of125I-Labeled β-amyloid peptide AB1-40through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ1-40/vector complex,”Proc. Natl. Acad. Sci. USA, 1995, 92:10227-10231.
Saji, “Targeted Delivery of Radiolabeled Imaging and Therapeutic Agents: Bifunctional Radiopharmaceuticals,”Crit. Rev. Ther. Drug Carrier Syst., 1999, 16(2):209-244.
Sipkins et al., “Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging,”Nature Med., 1998, 4(5):623-626.
Wang et al., “Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia,”Proc. Natl. Acad. Sci. USA, 1999, 96:10373-10378.
Zanusso et al., “Prion protein expression in different species: Analysis with a panel of new mAbs,”Proc. Natl. Acad. Sci. USA, 1998, 95:8812-8816.
Foldi et al., “The Test for Severe Impairment: Validity with the Dementia Rating Scale and Utility as a Longitudinal Measure”, The Clinical Neuropsychologist, 1999, 13(1):22-29.
McKhann et al., “Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease”, Neurology, 1984, 34 (7):939-944.
Folstein et al., ““Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician”, J Psychiatr Res., 1975, 12(3):189-198.
Wilkison et al., “Psychogeriatric Dependency Rating Scales (PGDRS), A Method of Assessment for Use by Nurses”, Brit. J. Psychiat. ( 1980), 137:558-565.
Juva et al., “Staging the severity of dementia: comparison of clinical (CDR, DSM-III-R), functional (ADL, IADL) and cognitive (MMSE) scales”, Acta Neurol. Acand., 1994, 90:293-298.
Curran Geoffry L.
Poduslo Joseph F.
Chernyshev Olga N
Mayo Foundation for Medical Education and Research
Quarles & Brady LLP
LandOfFree
Treatment for central nervous system disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for central nervous system disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for central nervous system disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692360